Plasma Fractionation Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DM1900 | Last Updated On: Jul 18 2022 | Available Formats

> Global Plasma Fractionation Market Expected to reach a high CAGR of 7% By 2029: DataM Intelligence

Global Plasma Fractionation Market is segmented by Product (Albumin, Immunoglobulins, and coagulation Factor Concentrates), by Application (Neurology, Hematology, Immunology, Critical Care and Others), By End-User (Hospitals, and Research Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

The "Plasma Fractionation Market" is projected to grow at a CAGR of 7% during the forecast period 2022-2029.

Plasma fractionation is a method of separating various components of blood plasma to treat protein deficiency in individuals and also in industrial applications as packaging material. It is used in the prevention and treatment of life-threatening diseases caused by trauma, immunologic disorders, and infections.

Market Dynamics

The rising prevalence of respiratory diseases and alpha-1 antitrypsin deficiency (ATTD) along with the growing geriatric population, increasing use of immunoglobulins in various therapeutic applications are some of the factors driving the growth of the plasma fractionation market. 

Alpha-1 Antitrypsin (AAT) is a protein made in the liver in healthy humans, and certain genetic defects diminish or eliminate the liver’s ability to make AAT. An AAT deficiency causes a variety of conditions, including emphysema, neonatal hepatitis, jaundice, and chronic obstructive pulmonary disease (COPD). Alpha1-antitrypsin deficiency (AATD) is one of the most common genetic disorders associated with significant morbidity and mortality. The prevalence of diagnosed AATD increases with age. According to the European Respiratory Journal, 2017, it is estimated that the number of diagnosed AATD patients in Germany was 19 162, of whom an estimated 8684 patients would have had an additional pulmonary diagnosis. The prevalence of COPD and emphysema in AATD was 32% and 21%, respectively. In addition, according to the WHO, Respiratory diseases are the leading causes of death and disability in the world. About 65 million people suffer from the chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. Hence, the rising prevalence of various respiratory diseases and Alpha1-antitrypsin deficiency (AATD) is driving the growth of the plasma fractionation market globally.

Various advancements in the product by major manufacturers is also one of the major factor contributing to the growth of the market. For instance, in June 2019, Grifols, launched the VISTASEAL™ fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Also, in September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.

However, the high cost of plasma products, the emergence of recombinant alternatives, and limited reimbursements are some of the factors hindering the growth of the plasma fractionation market during the forecast period.

Market Segmentation

By product, the plasma fractionation market is segmented into albumin, immunoglobulins, coagulation factor concentrates, protease inhibitors, and others. Among these, the immunoglobulin segment accounted for the largest market share in 2018 and is expected to dominate the plasma fractionation market during the forecast period (2020-2027). The immunoglobulins segment is further classified into subcutaneous immunoglobulins, intravenous immunoglobulins, and others. The intravenous immunoglobulins (IVIg) held the largest market share in 2018 as it is the most extensively used plasma product globally for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, dermatomyositis, hypogammaglobinemia, Guillain-Barre syndrome, immune cytopenias, primary antibody deficiency, vacuities, asthma, and systemic lupus erythematosus, among other disorders. The rising prevalence of these disorders is fuelling the growth of this segment. The subcutaneous immunoglobulins (SCIg) segment is estimated to grow at the highest CAGR during the forecast period (2020-2027). SCIg has several advantages over IVIg such as; it is the best alternative for patients with limited vascular access who cannot tolerate adverse effects associated with IVIg. Slow administration and absorption of SCIg reduce the rapid variation in serum Ig levels, which further reduces adverse drug reactions. These advantages are expected to drive the growth in this product segment. The major players are innovating new products which lead to the growth of the immunoglobulins market. For instance, in September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.


The coagulation factor market is segmented into Von Willebrand Factor, Factor IX, Factor VIII, Factor XIII, Fibrinogen Concentrates, and Prothrombin Complex. Among these, the concentrate Factor VIII segment held the highest share in the coagulation factor concentrates market, owing to the rising geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies in developing countries for a majority of hemophilia patients is also expected to drive the growth of this segment.

Geographical Analysis

North America holds the dominant market share for plasma fractionation in 2018, and it is expected to maintain the growth over the forecast period, owing to increasing use of immunoglobulins in various applications such as neurological and autoimmune diseases. The growing number of respiratory diseases will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America. The burden of respiratory diseases is increasing in United States. According to the National Center for Health Statistics, currently, more than 25 million people in the United States have asthma and approximately 14.8 million adults have been diagnosed with COPD. COPD is the 4th leading cause of death in the United States.

According to the Centers for Disease Control and Prevention (CDC), in 2014, approximately 142,000 individuals died from COPD, and almost as many died from lung cancer (approximately 155,500) in the same year. In nearly 8 out of 10 cases, COPD is caused by exposure to cigarette smoke. Other environmental exposures (such as those in the workplace) may also cause COPD.

There are advancements in processes, improved formulations, and increased production efficiency. Advancement in technology leads to an improved process of plasma manufacturing, hence leading to the growth of the market in this region. There are many clinics across the region for targeted gene therapies with new advancements in treatments related to cardiovascular diseases, cancer immunotherapies, and blood-related disorders. Several innovations in manufacturing processes (e.g. improvement of yield), product developments (e.g. such as subcutaneous IG, IVIg 10% concentration, and IVIg liquid presentation), presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA are also supporting the growth of the plasma fractionation market in these regions. For instance, in August 2016, Shire, announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD). The treatment is also the first in the United States that has the option to dose recombinant von Willebrand factor (rVWF) independent of recombinant Factor VIII (rFVIII), based on patient need. This attribute allows for tailored treatment for patients who may not require additional FVIII.

Competitive Landscape

The Plasma Fractionation market is dominated by a few major players including CSL, Grifols, China Biologic Products, Shire (Takeda Pharmaceutical Company), Octapharma Plasma, Inc., Kedrion S.p.A, Sanquin, and LFB SA. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Plasma Fractionation market globally. For instance, 

In June 2019, Grifols, one of the world’s three top providers of plasma-derived medicines to treat life-threatening diseases, launched the VISTASEAL™ fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. 

In March 2019, Grifols acquired $1.9 billion stakes in Shanghai RAAS Blood Products Co., gaining a major foothold in China’s booming blood-products market.

In January 2019, Takeda Pharmaceutical Company Limited (Japan), a global biopharmaceutical company acquired the Shire, increasing its geographic footprint and global customer base.

In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.

In September 2018, Octapharma invested USD 25 million (Euro 21 million) in a new multi-function facility in Springe, Germany, that will have a new production line for human normal immunoglobulin panzyga, alongside human albumin and album.

In August 2018, Grifols acquired Biotest US Corporation, a subsidiary of Biotest (Germany), to expand its plasma collection network with the addition of 24 Biotest centers in the US.

In February 2018, Guizhou Taibang Biological Products Co. Ltd., a wholly-owned subsidiary of China Biologic Products Organization, received approval from the Hainan Provincial Health and Family Planning Commission to build a new plasma collection station in Hainan Province.

Why Purchase the Report?

  • Visualize the composition of the plasma fractionation products in various applications highlighting the key commercial assets and players.

  • Identify commercial opportunities in plasma fractionation market by analyzing trends and co-development deals. 

  • Excel data sheet with thousands of data points of plasma fractionation market-level 4/5 segmentation.

  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the key product of all major market players

Target Audience

Trending Topics

Plasma Lighting Market

Renal Biomarkers Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest